Promising Preclinical Data for ATNM-400 Reinforces Buy Rating for Actinium Pharmaceuticals

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals and keeping the price target at $4.00.

Joseph Pantginis’s rating is based on the promising preclinical data for Actinium Pharmaceuticals’ ATNM-400, which demonstrates significant anti-tumor activity across various breast cancer models. The data presented at the San Antonio Breast Cancer Symposium highlight ATNM-400’s effectiveness in hormone receptor-positive and triple-negative breast cancer models, including those resistant to standard therapies like tamoxifen and trastuzumab.
The broad applicability of ATNM-400 across solid tumors, as evidenced by its performance in prostate and non-small cell lung cancer models, further supports its potential as a versatile treatment option. Pantginis is encouraged by the potential of ATNM-400 to address unmet needs in breast cancer treatment, particularly in cases where resistance to existing therapies is a challenge, reinforcing his Buy rating for Actinium Pharmaceuticals.